Related Experiment Video
Updated: Jul 13, 2026
10:28
An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
Published on: June 7, 2015
A novel, tissue occlusive poly(ethylene glycol) hydrogel material
Sandra Wechsler1, Daniel Fehr, Aart Molenberg
1Institute for Biomedical Engineering, Swiss Federal Institute of Technology and University of Zurich, Moussonstrasse 18, CH-8044 Zurich, Switzerland.
Journal of Biomedical Materials Research. Part A
|August 11, 2007
Summary
This study introduces a novel biodegradable poly (ethylene glycol) (PEG) hydrogel for guided bone regeneration (GBR). The PEG material effectively functions as a tissue occlusive membrane for at least six months, showing great potential for GBR applications.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Tissue Engineering
Background:
- Guided bone regeneration (GBR) requires advanced materials for clinical success.
- Key design criteria for GBR devices include biocompatibility, tissue occlusion, space provision, and manageability.
Purpose of the Study:
- To evaluate a novel biodegradable poly (ethylene glycol) (PEG) hydrogel as a tissue occlusive membrane for GBR.
- To assess the barrier function and degradation profile of PEG hydrogels in vivo and in vitro.
Main Methods:
- A subcutaneous implant model in rats was used to test the barrier function of PEG hydrogels.
- Histological analysis of explants collected over 7 months.
- In vitro degradation studies of PEG constructs.
Main Results:
- PEG hydrogels demonstrated significantly lower cellular infiltration (<1% of controls) for at least 4 months.
- Effective tissue occlusion and barrier function were maintained for up to 6 months in vivo.
- In vitro degradation studies corroborated the in vivo findings.
Conclusions:
- The novel PEG-based hydrogel shows potential as a viable tissue occlusive membrane for GBR applications.
- The material exhibits favorable biocompatibility and barrier properties over an extended period.
- Further research is warranted to explore its full clinical applicability in GBR.
